Onyx Healthcare reported September revenue of NT$124 million, marking a monthly and annual increase of over 30%. Cumulative revenue for the first nine months of 2025 reached NT$998 million, representing a 16.2% year-on-year growth. Looking ahead to the second half of the year, the company stated that its three major product lines are steadily driving overall business performance upward. Fourth-quarter revenue is expected to climb further, aiming to hit a new high for the year, with growth momentum projected to extend through 2026 while maintaining stable gross margins.
For the first half of 2025, Onyx Healthcare posted operating revenue of NT$667 million, up 16.14% year-on-year. However, due to exchange rate fluctuations and the clearance of some long-term stagnant inventory, operating income and pre-tax profit slightly declined compared to the same period last year, resulting in earnings per share (EPS) of NT$0.81. During a recent investors’ conference, the company noted that its second-quarter gross margin had returned to normal levels. The stagnant inventory cleared in the first quarter totaled approximately NT$15 million. Overall, the gross margin was impacted by foreign exchange fluctuations by about four percentage points; excluding this factor, the company’s performance would have been even stronger.
Onyx Healthcare observed that the main driver of growth in smart healthcare is the accelerated implementation of artificial intelligence. The application of medical AI now spans emergency care, surgery, inpatient wards, and home care. With the adoption of edge AI servers in ambulances and emergency departments, hospitals can process imaging data in real time, significantly improving diagnostic efficiency and treatment success rates.
In surgical applications, AI is used for 3D image modeling, navigation, and surgical planning. In hospital wards, it enables remote monitoring and non-contact physiological measurement, while AI-assisted alert systems support medical staff in responding promptly to patient needs. Home care is also evolving from simple health management toward home-based medical services and preventive medicine, with AI-powered monitoring devices seeing increasing penetration in the long-term care market.
Looking to 2025, Onyx Healthcare’s global operations are advancing along three strategic directions: continuing to strengthen its existing smart hospital IT equipment business, deepening its focus on medical AI instrument OEM/ODM services, and expanding into customized medical device manufacturing—now emerging as the company’s third growth engine. Onyx emphasized that operations are progressing on the right track, with rising demand for smart medical equipment, accelerated implementation of AI healthcare projects, and steady growth in customized QMS-based medical manufacturing orders. The company expects a sustained upward trend in the second half of the year, with fourth-quarter revenue poised to reach a new high for 2025, while maintaining stable gross margins and healthy long-term momentum.
Resource: 醫揚9月營收跳高，三軌並進，Q4營收拚登今年高峰
